Literature DB >> 34381257

Delays in Administration of the Second Antibiotic Dose in Patients With Severe Sepsis and Septic Shock.

Jana L Randolph1, Kin Chan2, Amanda Albright2, Aleda Chen3.   

Abstract

Purpose: The aim of this study was to determine the incidence of significant delays in administration of the second antibiotic dose in patients treated for severe sepsis and septic shock at a single community teaching hospital as well as to assess patient outcomes associated with second dose delays.
Methods: This single-center, retrospective chart review evaluated patients who received at least 2 antibiotic doses for severe sepsis or septic shock. Patients were classified as having experienced a significant second dose delay if the actual interval between the first and the second antibiotic doses was greater than or equal to 125% of the recommended dosing interval.
Results: Of 197 patients, 38 (19.3%) experienced a significant second antibiotic dose delay. The rate of significant delays was 17.1% in patients treated initially in the emergency department and 30.3% in patients treated initially in another inpatient location. Conclusions: This single-center study found a 19.3% rate of significant delays in antibiotic second dose administration in patients with severe sepsis and septic shock. This study was not powered to identify differences in outcomes in patients with and without significant second dose delays. Additional large-scale studies are needed to investigate the impact of antibiotic second dose delays on outcomes in patients with sepsis.
© The Author(s) 2019.

Entities:  

Keywords:  anti-infectives; critical care; drug; medical use evaluation; medication safety

Year:  2019        PMID: 34381257      PMCID: PMC8326874          DOI: 10.1177/0018578719889025

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  12 in total

1.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.

Authors:  Anand Kumar; Daniel Roberts; Kenneth E Wood; Bruce Light; Joseph E Parrillo; Satendra Sharma; Robert Suppes; Daniel Feinstein; Sergio Zanotti; Leo Taiberg; David Gurka; Aseem Kumar; Mary Cheang
Journal:  Crit Care Med       Date:  2006-06       Impact factor: 7.598

2.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuck Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Crit Care Med       Date:  2017-03       Impact factor: 7.598

3.  The Surviving Sepsis Campaign Bundle: 2018 Update.

Authors:  Mitchell M Levy; Laura E Evans; Andrew Rhodes
Journal:  Crit Care Med       Date:  2018-06       Impact factor: 7.598

4.  Time to Appropriate Antibiotic Therapy Is an Independent Determinant of Postinfection ICU and Hospital Lengths of Stay in Patients With Sepsis.

Authors:  David Zhang; Scott T Micek; Marin H Kollef
Journal:  Crit Care Med       Date:  2015-10       Impact factor: 7.598

5.  Delayed Second Dose Antibiotics for Patients Admitted From the Emergency Department With Sepsis: Prevalence, Risk Factors, and Outcomes.

Authors:  Daniel Leisman; Victor Huang; Qiuping Zhou; Jeanie Gribben; Andrea Bianculli; Michelle Bernshteyn; Mary Frances Ward; Sandra M Schneider
Journal:  Crit Care Med       Date:  2017-06       Impact factor: 7.598

6.  Gram-negative bacteremia induces greater magnitude of inflammatory response than Gram-positive bacteremia.

Authors:  Ryuzo Abe; Shigeto Oda; Tomohito Sadahiro; Masataka Nakamura; Yo Hirayama; Yoshihisa Tateishi; Koichiro Shinozaki; Hiroyuki Hirasawa
Journal:  Crit Care       Date:  2010-03-04       Impact factor: 9.097

7.  Risk factors for the development of acute lung injury in patients with septic shock: an observational cohort study.

Authors:  Remzi Iscimen; Rodrigo Cartin-Ceba; Murat Yilmaz; Hasrat Khan; Rolf D Hubmayr; Bekele Afessa; Ognjen Gajic
Journal:  Crit Care Med       Date:  2008-05       Impact factor: 7.598

8.  Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department.

Authors:  David F Gaieski; Mark E Mikkelsen; Roger A Band; Jesse M Pines; Richard Massone; Frances F Furia; Frances S Shofer; Munish Goyal
Journal:  Crit Care Med       Date:  2010-04       Impact factor: 7.598

9.  Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy.

Authors:  Sean M Bagshaw; Stephen Lapinsky; Sandra Dial; Yaseen Arabi; Peter Dodek; Gordon Wood; Paul Ellis; Jorge Guzman; John Marshall; Joseph E Parrillo; Yoanna Skrobik; Anand Kumar
Journal:  Intensive Care Med       Date:  2008-12-09       Impact factor: 17.440

10.  Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis.

Authors:  Jose Garnacho-Montero; Teresa Aldabo-Pallas; Carmen Garnacho-Montero; Aurelio Cayuela; Rocio Jiménez; Sonia Barroso; Carlos Ortiz-Leyba
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.